135 results
425
EX-4.1
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
such transaction is made on an arm’s-length basis and expressly approved by a majority of the disinterested directors of the Company (even if less than a quorum … traded securities and, directly or indirectly, are the holders of a majority of the voting power of the surviving entity (or entities with the authority
425
EX-10.2
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
filed under the 1933 Act covering the resale of Remaining Registrable Securities.
(u) “Required Holders” means the holders of at least a majority … Person, legal counsel referred to in the immediately preceding sentence shall be selected by the Investors holding at least a majority in interest
425
EX-2.1
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
“control” means the ownership of a majority of the voting securities of the applicable Person or the possession, directly or indirectly, of the power … granted under a Hepion Equity Plan.
“Hepion Stockholder Approval” means the vote of the majority of the shareholders of Hepion cast at a meeting
425
EX-10.1
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
the Closing Date, holders of at least a majority of the aggregate Principal Amount of Notes issued.
“Rule 144” means Rule 144 promulgated … ) of which more than 50% of (i) the outstanding equity interests having (in the absence of contingencies) ordinary voting power to elect a majority
8-K
EX-10.2
82gj8jy9
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
8-K
EX-4.1
28v5edx
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
8-K
EX-10.1
im06zkbmg0hegv yu4
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
8-K
EX-2.1
eryb boucsw
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
8-K
EX-4.1
1g7q3mmu kz5tolxi
16 Feb 24
Entry into a Material Definitive Agreement
9:02am
8-K
EX-10.1
i7fij9zac0wctvaprzn7
16 Feb 24
Entry into a Material Definitive Agreement
9:02am
8-K
EX-4.2
2dnhdlyy
16 Feb 24
Entry into a Material Definitive Agreement
9:02am
8-K
EX-4.1
ijn1 161f37
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
8-K
EX-4.3
5k892 iy10n1l
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
8-K
EX-10.1
5zwl3 pvhr
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
8-K
EX-4.2
6pecsjl1
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm